Answers are grounded in this paper and cite their sources.
For patients with femoropopliteal disease, DCB angioplasty is associated with better 2-year outcomes and similar target limb-related costs compared with standard PTA. Formal cost-effectiveness analysis on the basis of these results suggests that use of the DCB angioplasty is likely to be economically attractive.
No takes yet. Share an insight, caveat, or question.
Salisbury et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: